Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cerus Corporation stock logo
CERS
Cerus
$1.34
$1.33
$1.12
$2.54
$256.15M1.551.31 million shs1.33 million shs
Oculis Holding AG stock logo
OCS
Oculis
$19.28
-1.0%
$18.60
$10.79
$23.08
$841.77M0.3545,559 shs45,000 shs
PetIQ, Inc. stock logo
PETQ
PetIQ
$30.98
$30.90
$15.09
$31.06
$925.99M1.73480,624 shsN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
$1.41
$1.35
$0.89
$4.29
$60.48M0.84250,088 shs60,874 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cerus Corporation stock logo
CERS
Cerus
0.00%+1.52%+7.20%-14.10%-20.71%
Oculis Holding AG stock logo
OCS
Oculis
0.00%+1.37%+1.42%-1.68%+64.79%
PetIQ, Inc. stock logo
PETQ
PetIQ
0.00%0.00%0.00%0.00%+42.24%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
0.00%-3.89%+6.82%+30.56%-60.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cerus Corporation stock logo
CERS
Cerus
2.3087 of 5 stars
3.51.00.00.03.21.70.6
Oculis Holding AG stock logo
OCS
Oculis
2.0386 of 5 stars
3.53.00.00.01.90.00.6
PetIQ, Inc. stock logo
PETQ
PetIQ
N/AN/AN/AN/AN/AN/AN/AN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
2.7021 of 5 stars
3.33.00.00.02.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cerus Corporation stock logo
CERS
Cerus
3.00
Buy$3.50161.19% Upside
Oculis Holding AG stock logo
OCS
Oculis
3.00
Buy$35.3383.26% Upside
PetIQ, Inc. stock logo
PETQ
PetIQ
2.00
Hold$31.000.06% Upside
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
2.50
Moderate Buy$4.50219.15% Upside

Current Analyst Ratings Breakdown

Latest PETQ, OCS, RPTX, and CERS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Oculis Holding AG stock logo
OCS
Oculis
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$28.00 ➝ $33.00
4/17/2025
Oculis Holding AG stock logo
OCS
Oculis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$29.00 ➝ $32.00
4/17/2025
Oculis Holding AG stock logo
OCS
Oculis
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cerus Corporation stock logo
CERS
Cerus
$180.27M1.42N/AN/A$0.31 per share4.32
Oculis Holding AG stock logo
OCS
Oculis
$780K1,079.19N/AN/A$1.91 per share10.09
PetIQ, Inc. stock logo
PETQ
PetIQ
$1.10B0.84$2.68 per share11.54$7.58 per share4.09
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
$53.48M1.13N/AN/A$3.56 per share0.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cerus Corporation stock logo
CERS
Cerus
-$20.92M-$0.10N/AN/AN/A-10.23%-34.81%-9.68%7/30/2025 (Estimated)
Oculis Holding AG stock logo
OCS
Oculis
-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/26/2025 (Estimated)
PetIQ, Inc. stock logo
PETQ
PetIQ
$2.13M$0.3979.4424.59N/A1.20%18.75%5.15%N/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
-$84.69M-$3.01N/AN/AN/AN/A-78.12%-67.11%N/A

Latest PETQ, OCS, RPTX, and CERS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Oculis Holding AG stock logo
OCS
Oculis
-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million
5/1/2025Q1 2025
Cerus Corporation stock logo
CERS
Cerus
-$0.05-$0.04+$0.01-$0.04$47.44 million$43.24 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cerus Corporation stock logo
CERS
Cerus
N/AN/AN/AN/AN/A
Oculis Holding AG stock logo
OCS
Oculis
N/AN/AN/AN/AN/A
PetIQ, Inc. stock logo
PETQ
PetIQ
N/AN/AN/AN/AN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cerus Corporation stock logo
CERS
Cerus
1.15
2.32
1.63
Oculis Holding AG stock logo
OCS
Oculis
N/A
4.79
4.79
PetIQ, Inc. stock logo
PETQ
PetIQ
1.68
2.58
1.68
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
N/A
7.42
7.42

Institutional Ownership

CompanyInstitutional Ownership
Cerus Corporation stock logo
CERS
Cerus
78.37%
Oculis Holding AG stock logo
OCS
Oculis
22.30%
PetIQ, Inc. stock logo
PETQ
PetIQ
94.99%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
85.09%

Insider Ownership

CompanyInsider Ownership
Cerus Corporation stock logo
CERS
Cerus
3.40%
Oculis Holding AG stock logo
OCS
Oculis
N/A
PetIQ, Inc. stock logo
PETQ
PetIQ
9.62%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
11.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cerus Corporation stock logo
CERS
Cerus
290191.16 million184.66 millionOptionable
Oculis Holding AG stock logo
OCS
Oculis
243.66 millionN/ANot Optionable
PetIQ, Inc. stock logo
PETQ
PetIQ
1,93329.89 million27.01 millionOptionable
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
18042.89 million37.96 millionOptionable

Recent News About These Companies

Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds
Repare Therapeutics Names Forte as President, CEO
Repare Therapeutics Announces Leadership Transitions
Repare Therapeutics Reduces Workforce by 75 Percent
Repare Therapeutics reports Q4 EPS (67c), consensus (79c)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cerus stock logo

Cerus NASDAQ:CERS

$1.34 0.00 (0.00%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$1.31 -0.03 (-2.24%)
As of 06/20/2025 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Oculis stock logo

Oculis NASDAQ:OCS

$19.28 -0.20 (-1.03%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$19.17 -0.11 (-0.57%)
As of 06/20/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

PetIQ stock logo

PetIQ NASDAQ:PETQ

PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.

Repare Therapeutics stock logo

Repare Therapeutics NASDAQ:RPTX

$1.41 0.00 (0.00%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$1.40 -0.01 (-1.06%)
As of 06/20/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.